Agios Total Current Liabilities vs Cash And Short Term Investments Analysis

AGIO Stock  USD 38.17  5.20  11.99%   
Agios Pharm financial indicator trend analysis is way more than just evaluating Agios Pharm prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Agios Pharm is a good investment. Please check the relationship between Agios Pharm Total Current Liabilities and its Cash And Short Term Investments accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.

Total Current Liabilities vs Cash And Short Term Investments

Total Current Liabilities vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Agios Pharm Total Current Liabilities account and Cash And Short Term Investments. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Agios Pharm's Total Current Liabilities and Cash And Short Term Investments is 0.46. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Agios Pharm, assuming nothing else is changed. The correlation between historical values of Agios Pharm's Total Current Liabilities and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Agios Pharm are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Total Current Liabilities i.e., Agios Pharm's Total Current Liabilities and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

0.46
Relationship DirectionPositive 
Relationship StrengthWeak

Total Current Liabilities

Total Current Liabilities is an item on Agios Pharm balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Agios Pharm are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Agios Pharm balance sheet. This account contains Agios Pharm investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Agios Pharm fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.
Most indicators from Agios Pharm's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Agios Pharm current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.At this time, Agios Pharm's Sales General And Administrative To Revenue is very stable compared to the past year. As of the 13th of December 2024, Enterprise Value is likely to grow to about 1.5 B, while Selling General Administrative is likely to drop about 81.2 M.
 2021 2022 2023 2024 (projected)
Interest Expense836K12.8M14.7M15.4M
Depreciation And Amortization18.8M18.6M6.6M8.3M

Agios Pharm fundamental ratios Correlations

0.70.510.97-0.130.81-0.090.03-0.470.710.120.92-0.150.450.980.890.880.980.260.830.840.330.60.980.020.9
0.70.880.520.440.790.18-0.21-0.90.850.370.65-0.380.10.650.790.910.670.730.720.930.810.520.690.280.81
0.510.880.330.510.50.48-0.42-0.830.850.530.47-0.33-0.090.460.630.760.510.650.460.790.770.340.50.560.65
0.970.520.33-0.370.7-0.170.06-0.270.590.070.89-0.10.490.960.830.760.960.00.720.710.070.530.95-0.070.84
-0.130.440.51-0.370.090.48-0.32-0.480.220.35-0.150.05-0.4-0.13-0.040.18-0.190.840.170.190.82-0.02-0.120.47-0.03
0.810.790.50.70.09-0.330.35-0.70.62-0.190.77-0.490.360.710.80.860.760.560.880.860.580.610.79-0.210.82
-0.090.180.48-0.170.48-0.33-0.8-0.020.360.78-0.150.16-0.3-0.02-0.05-0.04-0.070.17-0.29-0.030.24-0.29-0.060.96-0.04
0.03-0.21-0.420.06-0.320.35-0.80.05-0.35-0.990.04-0.240.41-0.080.02-0.050.010.00.26-0.04-0.090.310.02-0.710.0
-0.47-0.9-0.83-0.27-0.48-0.7-0.020.05-0.67-0.18-0.460.45-0.02-0.37-0.66-0.8-0.45-0.76-0.61-0.86-0.82-0.52-0.44-0.12-0.68
0.710.850.850.590.220.620.36-0.35-0.670.480.74-0.350.040.670.740.810.660.450.520.810.560.370.650.410.78
0.120.370.530.070.35-0.190.78-0.99-0.180.480.10.17-0.340.220.130.210.130.1-0.110.20.19-0.210.120.710.15
0.920.650.470.89-0.150.77-0.150.04-0.460.740.1-0.260.290.890.780.810.830.230.730.790.290.490.83-0.10.82
-0.15-0.38-0.33-0.10.05-0.490.16-0.240.45-0.350.17-0.260.140.01-0.23-0.27-0.12-0.18-0.07-0.38-0.220.09-0.090.17-0.24
0.450.1-0.090.49-0.40.36-0.30.41-0.020.04-0.340.290.140.460.360.290.47-0.060.430.23-0.070.70.5-0.090.34
0.980.650.460.96-0.130.71-0.02-0.08-0.370.670.220.890.010.460.840.820.950.210.80.760.270.570.970.10.85
0.890.790.630.83-0.040.8-0.050.02-0.660.740.130.78-0.230.360.840.890.920.320.780.910.410.670.90.071.0
0.880.910.760.760.180.86-0.04-0.05-0.80.810.210.81-0.270.290.820.890.860.550.860.980.630.640.860.070.9
0.980.670.510.96-0.190.76-0.070.01-0.450.660.130.83-0.120.470.950.920.860.180.780.830.260.60.990.060.92
0.260.730.650.00.840.560.170.0-0.760.450.10.23-0.18-0.060.210.320.550.180.570.550.990.370.260.260.35
0.830.720.460.720.170.88-0.290.26-0.610.52-0.110.73-0.070.430.80.780.860.780.570.810.580.760.83-0.130.78
0.840.930.790.710.190.86-0.03-0.04-0.860.810.20.79-0.380.230.760.910.980.830.550.810.640.620.810.070.92
0.330.810.770.070.820.580.24-0.09-0.820.560.190.29-0.22-0.070.270.410.630.260.990.580.640.390.320.340.43
0.60.520.340.53-0.020.61-0.290.31-0.520.37-0.210.490.090.70.570.670.640.60.370.760.620.390.62-0.070.66
0.980.690.50.95-0.120.79-0.060.02-0.440.650.120.83-0.090.50.970.90.860.990.260.830.810.320.620.080.89
0.020.280.56-0.070.47-0.210.96-0.71-0.120.410.71-0.10.17-0.090.10.070.070.060.26-0.130.070.34-0.070.080.07
0.90.810.650.84-0.030.82-0.040.0-0.680.780.150.82-0.240.340.851.00.90.920.350.780.920.430.660.890.07
Click cells to compare fundamentals

Agios Pharm Account Relationship Matchups

Agios Pharm fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets890.7M853.0M1.4B1.2B937.1M752.6M
Other Current Liab53.1M61.9M32.0M30.4M28.2M28.5M
Total Current Liabilities92.9M94.4M59.8M62.6M68.0M75.2M
Total Stockholder Equity640.5M399.5M1.3B1.1B811.0M564.7M
Other Liab77.4M50.6M261.3M3.3M3.8M3.6M
Property Plant And Equipment Net126.1M117.5M104.2M88.1M69.8M52.5M
Net Debt32.7M(22.2M)(106.0M)(53.6M)(16.2M)(17.0M)
Retained Earnings(1.5B)(1.8B)(238.8M)(470.6M)(822.6M)(863.8M)
Accounts Payable21.9M17.7M16.7M18.6M9.8M15.1M
Cash80.9M127.4M203.1M139.3M88.2M83.8M
Non Current Assets Total279.0M216.3M373.5M405.9M103.3M178.4M
Non Currrent Assets Other(279.0M)1.1M2.9M4.0M4.1M4.3M
Cash And Short Term Investments564.9M670.5M1.3B1.1B776.9M637.5M
Common Stock Total Equity58K68K69K71K81.7K49.5K
Common Stock Shares Outstanding60.0M69.0M60.4M54.8M55.7M48.8M
Short Term Investments483.9M445.5M816.9M643.9M688.7M428.3M
Liabilities And Stockholders Equity890.7M853.0M1.4B1.2B937.1M752.6M
Non Current Liabilities Total157.3M359.1M85.9M75.3M58.1M112.7M
Other Current Assets24.2M49.1M39.8M39.0M35.0M22.1M
Other Stockholder Equity2.2B2.2B1.5B1.6B1.6B1.2B
Total Liab250.2M453.5M145.8M137.9M126.1M187.9M
Property Plant And Equipment Gross31.5M117.5M28.9M138.2M122.0M128.1M
Total Current Assets611.7M636.7M1.1B832.8M833.8M574.2M
Accumulated Other Comprehensive Income202K105K(1.2M)(12.5M)(441K)(463.1K)
Short Term Debt6.9M14.8M11.2M13.7M30.0M39.8M
Common Stock58K68K69K71K72K51.8K
Property Plant Equipment31.5M32.3M28.9M23.0M26.4M21.1M
Net Tangible Assets640.5M399.5M1.3B1.1B1.3B633.1M
Net Receivables15.3M25.4M4.4M2.2M2.8M2.7M
Retained Earnings Total Equity(1.5B)(1.8B)(238.8M)(470.6M)(423.5M)(444.7M)
Capital Surpluse2.2B2.2B2.3B2.4B2.7B1.7B
Inventory7.3M14.7M16.2M8.5M19.1M20.0M
Long Term Investments152.9M97.6M266.4M313.9M29.4M28.0M
Non Current Liabilities Other157.3M359.1M85.9M3.3M1.2M1.1M
Net Invested Capital640.5M399.5M1.3B1.1B811.0M833.9M
Net Working Capital518.8M542.3M1.0B770.1M765.9M702.8M

Pair Trading with Agios Pharm

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will appreciate offsetting losses from the drop in the long position's value.

Moving against Agios Stock

  0.7PFE Pfizer Inc Fiscal Year End 4th of February 2025 PairCorr
  0.64VALN Valneva SE ADRPairCorr
  0.64LLY Eli LillyPairCorr
  0.64IMAB I MabPairCorr
  0.58MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
The ability to find closely correlated positions to Agios Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharm to buy it.
The correlation of Agios Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agios Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Agios Pharm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Agios Pharm's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Agios Pharm Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Agios Pharm Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
10.26
Revenue Per Share
0.582
Quarterly Revenue Growth
0.212
Return On Assets
(0.18)
Return On Equity
0.5366
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.